6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort.
Florian Deisenhammer,Wegene Borena,A Bauer,Janine Kimpel,Dagmar Rudzki,Kathrin Schanda,Jonas Egeter,Katharina Hüfner,Barbara Sperner-Unterweger,Markus Reindl +9 more
TLDR
There is a stable and persisting antibody response against acute respiratory syndrome coronavirus 2 at 6 months after infection, and neutralizing antibodies confirm virus specificity.Abstract:
As coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 evolved only recently, the persistency of the anti-viral antibody response remains to be determined. We prospectively followed 29 coronavirus disease 2019 cases, mean age 44 ± 13.2 years. Except for one participant with a pre-existing diagnosis of rheumatoid arthritis, all other participants were previously healthy. We determined anti-viral binding antibodies at 2–10 weeks, 3 months, and 6 months after disease onset as well as neutralizing antibodies at 6 months. Two binding antibody assays were used, targeting the S1 subunit of the spike protein, and the receptor binding domain. All participants fully recovered spontaneously except for one who had persisting hyposmia. Antibodies to the receptor binding domain persisted for 6 months in all cases with a slight increase of titers, whereas antibodies to S1 dropped below the cut-off point in 2 participants and showed a minimal decrease on average, mainly at month 3 of follow-up in males; however, neutralizing antibodies were detected in all samples at 6 months of follow-up. There is a stable and persisting antibody response against acute respiratory syndrome coronavirus 2 at 6 months after infection. Neutralizing antibodies confirm virus specificity. As the number of coronavirus disease 2019 convalescent cases is increasing sharply, antibody testing should be implemented to identify immunized individuals. This information can be helpful in various settings of professional and private life.read more
Citations
More filters
Journal ArticleDOI
Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review.
TL;DR: In this paper, a systematic review conducted with a comprehensive search including formal databases, COVID-19 or SARS-CoV-2 data sources, grey literature, and manual search is presented.
Journal ArticleDOI
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Gabriel Bsteh,Sophie Dürauer,Hamid Assar,Harald Hegen,Bettina Heschl,Fritz Leutmezer,Franziska Di Pauli,Christiane Gradl,Gerhard Traxler,Gudrun Zulehner,Paulus S. Rommer,Peter Wipfler,Michael Guger,Romana Höftberger,Christian Enzinger,Thomas Berger +15 more
TL;DR: In this article, the authors evaluated degree, degree, and impact of disease-modifying treatment (DMT) on immunity after SARS-CoV-2 infection in patients with multiple sclerosis.
Journal ArticleDOI
Perceptions of Covid-19 lockdowns and related public health measures in Austria: a longitudinal online survey.
TL;DR: In this article, the authors compared the perceptions and experiences of the general population related to the first and second Covid-19 lockdowns in Austria and found that the extended duration of the pandemic and recurring lockdowns restricting freedom of movement and social contacts appear to have caused significant disruptions to many areas of life.
Journal ArticleDOI
Persistence of humoral response upon SARS-CoV-2 infection.
TL;DR: In this article, the authors summarize findings on the persistence of the humoral, including neutralizing antibody, response at three to eight months post SARS-CoV-2 infection in non-pregnant adults.
Journal ArticleDOI
The kinetics and predictors of anti‐SARS‐CoV‐2 antibodies up to 8 months after symptomatic COVID‐19: A Czech cross‐sectional study
TL;DR: Symptom count and duration in the acute phase of COVID‐19 are both relevant to the subsequent kinetics of antibody responses and the number of symptoms was the only predictor of persisting IgG seropositivity.
References
More filters
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Quanxin Long,Bai Zhong Liu,Hai Jun Deng,Gui Cheng Wu,Kun Deng,Yao Kai Chen,Pu Liao,Jing Fu Qiu,Yong Lin,Xue Fei Cai,Deqiang Wang,Yuan Hu,Ji Hua Ren,Ni Tang,Yin Yin Xu,Li Hua Yu,Zhan Mo,Fang Gong,Xiao-li Zhang,Wen Guang Tian,Li Hu,Xian Xiang Zhang,Jiang Lin Xiang,Hong Xin Du,Hua Wen Liu,Chun Hui Lang,Xiao He Luo,Shao Bo Wu,Xiao Ping Cui,Zheng Zhou,Man Man Zhu,Jing Wang,Cheng Jun Xue,Xiao Feng Li,Li Wang,Zhi Jie Li,Kun Wang,Chang Chun Niu,Qing Jun Yang,Xiaojun Tang,Yong Zhang,Xia Mao Liu,Jin Jing Li,De Chun Zhang,Fan Zhang,Liu Ping,Jun Yuan,Qin Li,Jie Li Hu,Juan Chen,Ailong Huang +50 more
TL;DR: It is suggested that SARS-CoV2-specific IgG or IgM seroconversion occurs within 20 days post symptom onset and may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections.
Journal ArticleDOI
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
Quanxin Long,Xiaojun Tang,Qiu Lin Shi,Qin Li,Hai Jun Deng,Jun Yuan,Jie Li Hu,Wei Xu,Yong Zhang,Fa Jin Lv,Kun Su,Fan Zhang,Jiang Gong,Bo Wu,Xia Mao Liu,Jin Jing Li,Jing Fu Qiu,Juan Chen,Ailong Huang +18 more
TL;DR: A cohort of asymptomatic patients infected with SARS-CoV-2 had significantly lower levels of virus-specific IgG antibodies compared to a cohort of age- and sex-matched symptomatic infected patients.
Journal ArticleDOI
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.
Juanjuan Zhao,Quan Yuan,Haiyan Wang,Wei Liu,Xuejiao Liao,Yingying Su,Xin Wang,Jing Yuan,Tingdong Li,Jinxiu Li,Shen Qian,Congming Hong,Fuxiang Wang,Yingxia Liu,Zhaoqin Wang,Qing He,Zhiyong Li,Bin He,Tianying Zhang,Yang Fu,Shengxiang Ge,Lei Liu,Jun Zhang,Ningshao Xia,Zheng Zhang +24 more
TL;DR: The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients and offer vital clinical information during the course of SARS-CoV-2 infection.